OS Therapies Incorporated (OSTX)

NYSEAMERICAN: OSTX · Real-Time Price · USD
1.630
+0.010 (0.62%)
Mar 26, 2025, 4:00 PM EST - Market closed
0.62%
Market Cap 34.62M
Revenue (ttm) n/a
Net Income (ttm) -7.42M
Shares Out 21.24M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 65,465
Open 1.630
Previous Close 1.620
Day's Range 1.570 - 1.680
52-Week Range 1.410 - 7.000
Beta n/a
Analysts Strong Buy
Price Target 17.50 (+973.62%)
Earnings Date May 15, 2025

About OSTX

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Mary... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 1, 2024
Employees 4
Stock Exchange NYSEAMERICAN
Ticker Symbol OSTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for OSTX stock is "Strong Buy." The 12-month stock price forecast is $17.5, which is an increase of 973.62% from the latest price.

Price Target
$17.5
(973.62% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

OS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

1 day ago - Business Wire

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

5 days ago - Business Wire

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that i...

13 days ago - Business Wire

OS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that i...

15 days ago - Business Wire

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the ...

Other symbols: CLDI
26 days ago - Accesswire

Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on February 27

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to inv...

4 weeks ago - Business Wire

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formatio...

4 weeks ago - Business Wire

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that i...

4 weeks ago - Business Wire

Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer

On Friday, OS Therapies, Inc. (NYSE-A: OSTX) entered into agreements for the commercial manufacture of OST-HER2.

5 weeks ago - Benzinga

OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that i...

5 weeks ago - Business Wire

OS Therapies Provides Corporate Update

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today provided a corpo...

7 weeks ago - Business Wire

OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy

OSTX's OST-HER2 immunotherapy is in a fully enrolled phase 2b trial for osteosarcoma, which had an updated readout in mid-January 2025. Financially, OSTX has $7.9 million in cash, with recent funding ...

2 months ago - Seeking Alpha

Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?

On Wednesday, OS Therapies, Inc. OSTX revealed data from a Phase 2b trial of OST-HER2 (OST31-164), a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of ...

2 months ago - Benzinga

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positi...

2 months ago - Business Wire

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that i...

2 months ago - Business Wire

OS Therapies Announces Closing of $6 Million Private Placement

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or the “Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced...

3 months ago - Business Wire

OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, has partnered with B2i...

3 months ago - Business Wire

OS Therapies Announces Pricing of $6 Million Private Placement

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced...

3 months ago - Business Wire

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported ...

4 months ago - Business Wire

OS Therapies to Present at The Spartan Capital Investor Conference

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced th...

5 months ago - Business Wire

Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased ...

5 months ago - Business Wire

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appo...

5 months ago - Business Wire

OS Therapies to Present at the LD Micro Main Event XVII

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces t...

5 months ago - Business Wire

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces t...

5 months ago - Business Wire

OSTX CEO: "We Have a Lot of Milestones Coming" in Tumor Research

Paul Romness, CEO of OS Therapies (OSTX), joins Nicole Petallides at the NYSE after the company recently completed a critical phase of its Osteosarcoma research. As OS Therapies readies to send its da...

6 months ago - Schwab Network